hotspot -WSS

hotspot

author：entertainment 2025-10-02 17:35:03 - browse：893

Peter Marks, Director of the Center for Biologics Evaluation and Research at the US Food and Drug Administration (FDA), testifies during a Senate Health, Education, Labor and Pensions Committee hearing to discuss the on-going federal response to Covid-19 on May 11, 2021 at the US Capitol in Washington, DC. — FDA's Peter Marks JIM LO SCALZO/POOL/AFP via Getty Images

WASHINGTON — The Food and Drug Administration needs dozens more reviewers if it wants its so-called Operation Warp Speed for rare disease therapies to take off, the agency’s biologics chief said Monday.

The administration launched the rare disease pilot program, dubbed START and modeled after the record race for a Covid-19 vaccine, this September. Peter Marks, head of the Center for Biologics Evaluation and Research, has spearheaded both initiatives.

“If we were really to expand this significantly, [it] would require us to get dozens of additional staff members,” Marks told listeners during a gene therapy discussion hosted by the Alliance for a Stronger FDA. “One could say ‘Oh my goodness, he’s asking for more headcount again.’ Well, if this really does reduce the time to development by 25 to 50% … it probably won’t take industry too long to do a net present value calculation to say ‘Oh, it’s worth making sure that they have their extra 20 or 30 or 40 reviewers.’”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Asbestos, a deadly carcinogen, banned by EPA

hotspot

WSS

Readout Newsletter: WuXi and Congress, Boundless Bio, etc.

Study says nonprofit hospitals fall short in charity care spending

Food as medicine: Medically tailored meals may get standardized

Neuroscience’s long legacy of racism

Eliminate the waiting period for sterilization covered by Medicaid

Readout Newsletter: Cardior, Regeneron, Nuvation, Dyne and more

focus

hotspot

explore

Tori Bowie and the unacceptable rates of Black maternal death

U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

Walensky prepares to leave CDC — and Congress — behind

Plastic surgeons increase patient psychiatric screenings

23andMe had bad news about my health. I wish a person had delivered it

Will generative AI in health care meet the fate of IBM's Dr. Watson?

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Donor acceptance rates hint at racial, gender bias in heart transplants: study

Affirmative action in medical school literally saved lives

Readout Newsletter: Bluebird, CVS, Contineum

knowledge

5 to watch: Tech startups trying to solve health care's staffing crisis

Merck drug for rare lung condition set for approval in U.S.

Gene editing the human germline: What are the risks?

Patient advocates debate FDA's accelerated approval process

Study says nonprofit hospitals fall short in charity care spending

Readout Newsletter: Geron, Novo Nordisk, WuXi updates

hotspot

focus

entertainment

hotspot